Inhibition of the cell cycle with chemical inhibitors: a targeted approach.
Genetic links between deregulation of the cell cycle and cancer are well established. There have been significant recent developments both in our understanding of the molecular mechanisms that control cell cycle progression and in methods for protein structure determination at atomic resolution. These advances have allowed the rational design of small molecules that modulate the cell cycle by competing for sites of protein-protein or protein-ATP interactions. There is considerable optimism that these compounds, a selection of which are here reviewed, will become clinically significant drugs.
Welburn
Julie P I
JP
Laboratory of Molecular Biophysics and Department of Biochemistry, South Parks Road, Oxford OX1 3QU, UK. welburn@biop.ox.ac.uk
Endicott
Jane A
JA
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects*; D051379:Mice; D008934:Mitogens / Q000037:antagonists & inhibitors*; D008958:Models, Molecular; D009687:Nuclear Proteins / Q000378:metabolism; D011485:Protein Binding; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D051736:Proto-Oncogene Proteins c-mdm2; D015398:Signal Transduction / Q000187:drug effects; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
D000970:Antineoplastic Agents; D008934:Mitogens; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; C497207:Mdm2 protein, mouse; D051736:Proto-Oncogene Proteins c-mdm2